HC Wainwright Reiterates Buy Rating for Protara Therapeutics (NASDAQ:TARA)

HC Wainwright reaffirmed their buy rating on shares of Protara Therapeutics (NASDAQ:TARA) in a research report report published on Thursday morning,Benzinga reports. They currently have a $23.00 target price on the stock.

Separately, Guggenheim reiterated a “buy” rating and set a $20.00 target price on shares of Protara Therapeutics in a research note on Friday, December 6th.

Protara Therapeutics Stock Performance

Protara Therapeutics stock opened at $3.92 on Thursday. Protara Therapeutics has a 52 week low of $1.60 and a 52 week high of $10.48. The firm has a market capitalization of $80.87 million, a PE ratio of -1.39 and a beta of 1.69. The business’s 50-day simple moving average is $4.59 and its 200-day simple moving average is $3.39.

Protara Therapeutics (NASDAQ:TARA) last issued its quarterly earnings results on Wednesday, March 12th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.09. Research analysts forecast that Protara Therapeutics will post -3.32 earnings per share for the current year.

Institutional Trading of Protara Therapeutics

Several institutional investors have recently modified their holdings of the company. XTX Topco Ltd acquired a new position in shares of Protara Therapeutics in the third quarter valued at $60,000. HBK Investments L P bought a new stake in Protara Therapeutics in the 4th quarter valued at $106,000. Squarepoint Ops LLC acquired a new position in shares of Protara Therapeutics in the 4th quarter valued at $110,000. Dimensional Fund Advisors LP acquired a new position in shares of Protara Therapeutics in the 4th quarter valued at $111,000. Finally, Bailard Inc. bought a new position in shares of Protara Therapeutics during the 4th quarter worth about $157,000. Institutional investors and hedge funds own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.